Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
Retrospective biomarker findings underpin planned prospective testing of lifileucel in previously treated and frontline lung cancer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) reported a 24.6% objective response rate with lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer.
At the October 14, 2026 cutoff, 17 of 69 patients responded in Phase 2 IOV-LUN-202, versus 25.6% in 39 patients previously. Two responses await confirmation. Objective response rate measures the proportion of patients whose tumors shrink or disappear. A retrospective analysis showed 43.3% response in KRAS wild-type disease versus 11.4% in KRAS-mutant disease; a further biomarker-enriched subgroup had 59.1% response in 22 patients.
Cohorts 1 and 2 are completing enrollment, with approximately 80 patients expected in the final dataset. Iovance plans a supplemental approval application in 2027. Biomarker-selected POSITILITY enrollment is to begin in November 2026, with a potential registration pathway subject to FDA feedback. The company also plans the frontline OPTILISM trial in 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointLifileucel response rate was 24.6% in 69 patients, consistent with 25.6% in 39 patients previously.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Iovance plans a 2027 supplemental approval application for lifileucel in non-squamous metastatic lung cancer.
- Minor pointKRAS wild-type response rate was 43.3% (13/30), versus 11.4% (4/35) in KRAS-mutant disease.
- Minor pointKRAS wild-type plus HER2 wild-type subgroup achieved 52.0% response (13/25).
- Minor pointCombined biomarker-enriched subgroup achieved 59.1% response (13/22), including both complete responses.
6 minor points
- Minor pointResponse durability and safety remained consistent with previous reports.
- Minor pointUpdated reduced-dose lymphodepletion, the preparatory treatment regimen, improved the overall safety profile.
- Minor point. Forward-looking: it has not happened yet and may not happen.Cohorts 1 and 2 are completing enrollment, with approximately 80 patients expected in the final dataset.
- Minor point. Forward-looking: it has not happened yet and may not happen.POSITILITY prospective biomarker-enriched enrollment is to begin in November 2026.
- Minor pointFrontline lifileucel plus pembrolizumab produced 85.7% response (6/7) in the specified KRAS wild-type smoking-history subgroup.
- Minor point. Forward-looking: it has not happened yet and may not happen.Iovance plans to initiate OPTILISM in 2027, testing frontline treatment in biomarker-enriched disease.
Negative
- Minor pointReported response rates include two unconfirmed partial responses; independent review committee assessments remain ongoing.
- Minor point. Forward-looking: it has not happened yet and may not happen.Biomarker-enrichment findings are retrospective; prospective evaluation is planned through POSITILITY.
- Minor pointPOSITILITY's potential registration pathway remains subject to FDA feedback.
- Minor pointFrontline subgroup findings involve seven patients; HER2 status was not assessed.
News Explained
A separate frontline IOV-COM-202 Cohort 3A analysis reported responses in six of seven patients with KRAS-wild-type tumors and current or former smoking history receiving lifileucel plus pembrolizumab without chemotherapy (
Details
Market move: IOVA -32.26% vs previous close. Phase 2 mNSCLC clinical data
On Oct 29, the day this news came out, the latest delayed price for IOVA is 32.26% below the previous close. Our momentum scanner has recorded 77 alerts for this stock so far that day. The latest delayed price is $10.03. Relative volume is exceptionally heavy at 182.9x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Objective response rate
- 24.6% (17/69 patients)
- Phase 2 IOV-LUN-202 Cohorts 1 and 2; October 14, 2026 data cutoff
- KRAS subgroup response rates
- 43.3% (13/30) KRAS wild-type vs. 11.4% (4/35) KRAS-mutant
- IOV-LUN-202 broader non-squamous mNSCLC population
- Biomarker-enriched subgroup ORR
- 59.1% (13/22 patients)
- KRAS wild-type, HER2 wild-type, and current or former smoking
- Frontline Cohort 3A ORR
- 85.7% (6/7 patients)
- Lifileucel plus pembrolizumab without chemotherapy; KRAS wild-type and current or former smoking
- Planned sBLA
- 2027
- Lifileucel for non-squamous mNSCLC
- POSITILITY enrollment
- November 2026
- Biomarker-enriched Phase 2 cohort
Key Terms
objective response rate (orr) medical
supplemental biologics license application (sbla) regulatory
lymphodepletion regimen medical
immune checkpoint inhibitor therapy medical
tumor microenvironment medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027
KRAS Wild-Type Subgroup Achieved
POSITILITY, a First-In-Class Biomarker-Enriched Study with Registrational Intent, to Begin Enrollment in November 2026
PHILADELPHIA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company developing and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer, today announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial and a first-in-class biomarker-enriched precision TIL strategy for lifileucel in previously treated non-squamous mNSCLC.
IOV-LUN-202 Cohorts 1 and 2 are completing enrollment and support the planned sBLA for lifileucel in non-squamous mNSCLC in 2027.
As of the October 14, 2026 data cutoff, 17 of 69 patients responded, representing an ORR of
A retrospective analysis identified a biomarker-enriched subgroup defined by Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type status, human epidermal growth factor receptor 2 (HER2) wild-type status, and current or former smoking. This subgroup represented less than one-third of the broader study population (22 of 69 patients) but accounted for more than three-quarters of the observed responses (13 of 17), with an ORR of
The KRAS findings and further biomarker enrichment provide the clinical foundation for Iovance’s precision TIL strategy. Iovance will prospectively evaluate this novel approach with POSITILITY, a first-in-class, prospective, biomarker-enriched cohort within the Phase 2 IOV-LUN-202 trial, designed with registrational intent.
Updated Results in the Broader Non-Squamous mNSCLC Population
Updated results from Cohorts 1 and 2 include 30 additional patients, bringing the total to 69 patients with non-squamous mNSCLC whose disease had progressed on or after platinum-based chemotherapy and immune checkpoint inhibitor therapy. Patients were enrolled without prospective selection using the novel biomarker-enrichment criteria.
The 17 reported responses included 15 confirmed responses and two unconfirmed partial responses (uPRs) awaiting confirmation. Radiologic assessments by an independent review committee are ongoing.
Response durability and the safety profile remained consistent with previous reports. The study incorporates an updated, reduced-dose lymphodepletion regimen that has improved the overall safety profile.
The broader IOV-LUN-202 Cohorts 1 and 2 are completing enrollment, with approximately 80 non-squamous NSCLC patients expected in the final dataset, and an sBLA for lifileucel in non-squamous mNSCLC is planned for 2027. Discussions with the U.S. Food and Drug Administration (FDA) are ongoing, and Iovance expects to provide further updates on the broader-population program in 2027.
KRAS Wild-Type Status Anchors the Precision TIL Strategy
To understand differences in response, Iovance evaluated clinical outcomes alongside tumor genomic and translational data. The analysis focused on tumor antigen presentation—the process by which tumor cells display targets for recognition by polyclonal TIL—and immune activity within the tumor microenvironment. Published preclinical studies in lung cancer models have linked oncogenic KRAS signaling to impaired antigen presentation and immune suppression, providing a biological rationale for investigating the association between KRAS status and response to lifileucel.1
KRAS status emerged as the lead biomarker for Iovance’s novel enrichment strategy. In the broader population of 69 patients with non-squamous mNSCLC, the ORR was
Building on this signal, Iovance incorporated HER2 wild-type status and current or former smoking status into its enrichment strategy. These criteria draw on standard tumor genomic testing and routinely collected smoking history. Preclinical research suggests that aberrant HER2 signaling can suppress antitumor immunity, while smoking-associated mutations generate additional tumor targets for recognition by polyclonal TIL.
All 13 responses in the KRAS wild-type subgroup occurred among the 22 patients meeting the combined enrichment criteria, yielding an ORR of
| Population | n | ORR* |
| Broader non-squamous NSCLC population | 69 | |
| KRAS wild-type | 30 | |
| KRAS-mutant | 35 | |
| KRAS wild-type + HER2 wild-type | 25 | |
| KRAS wild-type + HER2 wild-type + ever smoker | 22 |
*ORRs include two uPRs, pending confirmation: one in the KRAS wild-type group and one in the KRAS-mutant group. Four KRAS-unassessed patients are excluded.
“These findings are reshaping how we develop TIL therapy for mNSCLC,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance. “The expanded dataset reinforces the activity of lifileucel in previously treated disease, while the concentration of responses in KRAS wild-type tumors points to a more precision approach to patient selection. In the enriched subgroup, nearly six in ten patients responded, including two complete responses. We believe these insights could expand lifileucel’s potential as a one-time treatment for mNSCLC, with a best-in-class profile compared to other therapies in development.”
Iovance has launched POSITILITY as a first-in-class, prospective, biomarker-enriched cohort within the ongoing IOV-LUN-202 program, with enrollment to begin in November 2026 at the first of over 70 existing IOV-LUN-202 sites. Iovance intends for the study to support a potential registrational pathway, subject to FDA feedback.
“Tumor-reactive T cells need recognizable targets and a tumor microenvironment that supports a sustained antitumor response,” said Wayne Rothbaum, co-Chair of the Scientific Committee of Iovance’s Board of Directors. “The response pattern in IOV-LUN-202 provided a clinical rationale for testing how tumor biology can guide TIL therapy. Starting with KRAS status, and refining selection through HER2 status and smoking history, we identified a highly responsive mNSCLC subgroup where TIL biology converges with an immuno-reactive tumor microenvironment. We now aim to translate these novel findings into a precision development plan utilizing KRAS-based stratification, designed to identify patients most likely to benefit from lifileucel therapy.”
Supporting Frontline Data and Development Plans
In a separate analysis of frontline Cohort 3A of IOV-COM-202, six of seven patients with non-squamous mNSCLC, KRAS wild-type tumors, and a current or former smoking history responded to lifileucel plus pembrolizumab (without chemotherapy), yielding an ORR of
Iovance plans to initiate OPTILISM, an innovative, frontline trial in biomarker-enriched non-squamous mNSCLC, in 2027. OPTILISM and the second-line POSITILITY trial are intended to evaluate lifileucel across two treatment settings and assess the role of biomarker-guided patient selection within the mNSCLC development program.
Across the patient populations enrolling into OPTILISM and POSITILITY, the prevalence of the biomarker-enriched population is estimated at approximately
Additional details on the clinical results and development plans are available in a presentation posted to the Investor Relations section of www.iovance.com.
About IOV-LUN-202
IOV-LUN-202 is a Phase 2 study evaluating lifileucel in patients with previously treated mNSCLC. This update reports results from the 69 patients in Cohorts 1 and 2 with non-squamous histology who received a total viable cell count of at least 10 billion. Lifileucel remains investigational for the treatment of mNSCLC.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Iovance owns patent rights and other intellectual property rights related to the biomarker-directed strategy described in this press release. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.
References
1. Mugarza E, et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Science Advances. 2022;8:eabm8780. https://doi.org/10.1126/sciadv.abm8780
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements.
Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the size of the addressable patient populations for, and the acceptance by the market of, our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our iCTC facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial supply or clinical supply; the risks related to our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates, including our biomarker-directed strategy; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates and any required companion diagnostics; whether clinical trial results from our clinical studies and cohorts, and meetings with regulatory authorities, may support registrational studies, including biomarker-selected studies such as POSITILITY, and subsequent approvals by regulatory authorities, and the risk that our clinical trials, including registrational trials, may experience delays in site activation, enrollment, or data readouts, may not meet their primary endpoints, or may not support approval; clinical results, whether preliminary, interim, or final, which may include efficacy and safety results, from clinical trials or cohorts, including retrospective subgroup analyses, may not be confirmed or reflected in independent review assessments or the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior or future trials or cohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials, including comparisons to other therapies, or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities or others; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Iovance's updated IOV-LUN-202 trial show for lifileucel in lung cancer?
Lifileucel produced a 24.6% objective response rate (17/69) in previously treated non-squamous metastatic non-small-cell lung cancer at the October 14, 2026 cutoff. The responses included 15 confirmed responses and two unconfirmed partial responses awaiting confirmation. The previously reported rate was 25.6% in 39 patients.
When will Iovance begin POSITILITY and OPTILISM enrollment or development?
POSITILITY enrollment is to begin in November 2026, while Iovance plans to initiate OPTILISM in 2027. POSITILITY is a prospective biomarker-enriched cohort within Phase 2 IOV-LUN-202 for previously treated disease. OPTILISM will evaluate frontline treatment. POSITILITY's potential registration pathway is subject to FDA feedback.
Which biomarkers define Iovance's enriched lifileucel lung cancer subgroup?
The subgroup combines KRAS wild-type status, HER2 wild-type status, and current or former smoking. Wild-type means the tested gene does not have the relevant mutation. These criteria use standard tumor genomic testing and routinely collected smoking history. The subgroup represented 31.9% of the broader study population but accounted for 76.5% of observed responses.